News should be ready to drop on several fronts:
>Our merger with Baudax
>The resubmission of our EUA application to the FDA with copy to MHRA in UK
>Tentative regulatory approval for lenz to treat CMML, granted by Australia's Therapeutic Goods Administration
>A finding to continue the study of lenz based on results from the first 20 patients in the aGvHD trial, which could prove to be a cure for certain cancers
>The declaration of a 5:1 forward stock split, depending perhaps on concluding a planned business combination.
>And most importantly, and perhaps with the markets being closed Monday, announcement of the recall of our loaned shares. Our previous loaned shares recall was announced on a Thanksgiving Day.
Whether it happens or not remains to be seen. But we have seen evidence in support of each task I mentioned, and it is these tasks management is likely working on. The payout includes a forced covering of short positions, leading to a massive short squeeze, with management holding all the shares.
